167 related articles for article (PubMed ID: 36718088)
1. Retigabine suppresses loss of force in mouse models of hypokalaemic periodic paralysis.
Quiñonez M; DiFranco M; Wu F; Cannon SC
Brain; 2023 Apr; 146(4):1554-1560. PubMed ID: 36718088
[TBL] [Abstract][Full Text] [Related]
2. Beneficial effects of bumetanide in a CaV1.1-R528H mouse model of hypokalaemic periodic paralysis.
Wu F; Mi W; Cannon SC
Brain; 2013 Dec; 136(Pt 12):3766-74. PubMed ID: 24142145
[TBL] [Abstract][Full Text] [Related]
3. Voltage-dependent Ca
DiFranco M; Cannon SC
Am J Physiol Cell Physiol; 2022 Aug; 323(2):C478-C485. PubMed ID: 35759432
[TBL] [Abstract][Full Text] [Related]
4. A sodium channel knockin mutant (NaV1.4-R669H) mouse model of hypokalemic periodic paralysis.
Wu F; Mi W; Burns DK; Fu Y; Gray HF; Struyk AF; Cannon SC
J Clin Invest; 2011 Oct; 121(10):4082-94. PubMed ID: 21881211
[TBL] [Abstract][Full Text] [Related]
5. Mutations associated with hypokalemic periodic paralysis: from hotspot regions to complete analysis of CACNA1S and SCN4A genes.
Brugnoni R; Canioni E; Filosto M; Pini A; Tonin P; Rossi T; Canavese C; Eoli M; Siciliano G; Lauria G; Mantegazza R; Maggi L
Neurogenetics; 2022 Jan; 23(1):19-25. PubMed ID: 34608571
[TBL] [Abstract][Full Text] [Related]
6. A calcium channel mutant mouse model of hypokalemic periodic paralysis.
Wu F; Mi W; Hernández-Ochoa EO; Burns DK; Fu Y; Gray HF; Struyk AF; Schneider MF; Cannon SC
J Clin Invest; 2012 Dec; 122(12):4580-91. PubMed ID: 23187123
[TBL] [Abstract][Full Text] [Related]
7. Bumetanide prevents transient decreases in muscle force in murine hypokalemic periodic paralysis.
Wu F; Mi W; Cannon SC
Neurology; 2013 Mar; 80(12):1110-6. PubMed ID: 23427324
[TBL] [Abstract][Full Text] [Related]
8. Recovery from acidosis is a robust trigger for loss of force in murine hypokalemic periodic paralysis.
Mi W; Wu F; Quinonez M; DiFranco M; Cannon SC
J Gen Physiol; 2019 Apr; 151(4):555-566. PubMed ID: 30733232
[TBL] [Abstract][Full Text] [Related]
9. Hypokalaemic periodic paralysis type 2 caused by mutations at codon 672 in the muscle sodium channel gene SCN4A.
Sternberg D; Maisonobe T; Jurkat-Rott K; Nicole S; Launay E; Chauveau D; Tabti N; Lehmann-Horn F; Hainque B; Fontaine B
Brain; 2001 Jun; 124(Pt 6):1091-9. PubMed ID: 11353725
[TBL] [Abstract][Full Text] [Related]
10. Muscle edema of the lower limb determined by MRI in Asian hypokalaemic periodic paralysis patients.
Jia BX; Yang Q; Li SY; Wan M; Wang H; Huo LY; Zhao E; Ding YC; Ji XM; Guo XH
Neurol Res; 2015 Mar; 37(3):246-52. PubMed ID: 25213595
[TBL] [Abstract][Full Text] [Related]
11. Cardiac arrhythmias in hypokalemic periodic paralysis: Hypokalemia as only cause?
Stunnenberg BC; Deinum J; Links TP; Wilde AA; Franssen H; Drost G
Muscle Nerve; 2014 Sep; 50(3):327-32. PubMed ID: 25088161
[TBL] [Abstract][Full Text] [Related]
12. A204E mutation in Na
Kokunai Y; Dalle C; Vicart S; Sternberg D; Pouliot V; Bendahhou S; Fournier E; Chahine M; Fontaine B; Nicole S
Sci Rep; 2018 Nov; 8(1):16681. PubMed ID: 30420713
[TBL] [Abstract][Full Text] [Related]
13. The K
Tykocki NR; Heppner TJ; Dalsgaard T; Bonev AD; Nelson MT
J Physiol; 2019 Feb; 597(3):935-950. PubMed ID: 30536555
[TBL] [Abstract][Full Text] [Related]
14. The human skeletal muscle Na channel mutation R669H associated with hypokalemic periodic paralysis enhances slow inactivation.
Struyk AF; Scoggan KA; Bulman DE; Cannon SC
J Neurosci; 2000 Dec; 20(23):8610-7. PubMed ID: 11102465
[TBL] [Abstract][Full Text] [Related]
15. Enhanced inactivation and pH sensitivity of Na(+) channel mutations causing hypokalaemic periodic paralysis type II.
Kuzmenkin A; Muncan V; Jurkat-Rott K; Hang C; Lerche H; Lehmann-Horn F; Mitrovic N
Brain; 2002 Apr; 125(Pt 4):835-43. PubMed ID: 11912116
[TBL] [Abstract][Full Text] [Related]
16. Insulin acts in hypokalemic periodic paralysis by reducing inward rectifier K+ current.
Ruff RL
Neurology; 1999 Oct; 53(7):1556-63. PubMed ID: 10534267
[TBL] [Abstract][Full Text] [Related]
17. Muscle channelopathies: does the predicted channel gating pore offer new treatment insights for hypokalaemic periodic paralysis?
Matthews E; Hanna MG
J Physiol; 2010 Jun; 588(Pt 11):1879-86. PubMed ID: 20123788
[TBL] [Abstract][Full Text] [Related]
18. Treatment of myotonia congenita with retigabine in mice.
Dupont C; Denman KS; Hawash AA; Voss AA; Rich MM
Exp Neurol; 2019 May; 315():52-59. PubMed ID: 30738808
[TBL] [Abstract][Full Text] [Related]
19. Activation of KCNQ channels located on the skeletal muscle membrane by retigabine and its influence on the maximal muscle force in rat muscle strips.
Zagorchev P; Apostolova E; Kokova V; Peychev L
Naunyn Schmiedebergs Arch Pharmacol; 2016 Apr; 389(4):439-46. PubMed ID: 26815201
[TBL] [Abstract][Full Text] [Related]
20. Normal insulin release during sustained hyperglycaemia in hypokalaemic periodic paralysis: role of the potassium channel opener pinacidil in impaired muscle strength.
Ligtenberg JJ; Van Haeften TW; Van Der Kolk LE; Smit AJ; Sluiter WJ; Reitsma WD; Links TP
Clin Sci (Lond); 1996 Nov; 91(5):583-9. PubMed ID: 8942397
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
